Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

“Gilead’s restrictions on access to lenacapavir could allow the HIV epidemic to spread. This is the closest we have ever been ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

On the occasion of the 37th World AIDS Day, the Chinese Association of STD and AIDS Prevention and Control and China Youth ...